These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10501490)

  • 1. The appearance of escape variants in vivo does not account for the failure of recombinant envelope vaccines to protect against simian immunodeficiency virus.
    Almond N; Jenkins A; Jones S; Arnold C; Silvera P; Kent K; Mills KHG; Stott EJ
    J Gen Virol; 1999 Sep; 80 ( Pt 9)():2375-2382. PubMed ID: 10501490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.
    Mossman SP; Bex F; Berglund P; Arthos J; O'Neil SP; Riley D; Maul DH; Bruck C; Momin P; Burny A; Fultz PN; Mullins JI; Liljeström P; Hoover EA
    J Virol; 1996 Mar; 70(3):1953-60. PubMed ID: 8627721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.
    Schlienger K; Montefiori DC; Mancini M; Rivière Y; Tiollais P; Michel ML
    J Virol; 1994 Oct; 68(10):6578-88. PubMed ID: 7521918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).
    Hulskotte EG; Geretti AM; Siebelink KH; van Amerongen G; Cranage MP; Rud EW; Norley SG; de Vries P; Osterhaus AD
    J Virol; 1995 Oct; 69(10):6289-96. PubMed ID: 7666529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160.
    Hu SL; Stallard V; Abrams K; Barber GN; Kuller L; Langlois AJ; Morton WR; Benveniste RE
    J Med Primatol; 1993; 22(2-3):92-9. PubMed ID: 8411113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.
    Hu SL; Abrams K; Barber GN; Moran P; Zarling JM; Langlois AJ; Kuller L; Morton WR; Benveniste RE
    Science; 1992 Jan; 255(5043):456-9. PubMed ID: 1531159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus.
    Ahmad S; Lohman B; Marthas M; Giavedoni L; el-Amad Z; Haigwood NL; Scandella CJ; Gardner MB; Luciw PA; Yilma T
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):195-204. PubMed ID: 8198872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines.
    Israel ZR; Edmonson PF; Maul DH; O'Neil SP; Mossman SP; Thiriart C; Fabry L; Van Opstal O; Bruck C; Bex F
    J Virol; 1994 Mar; 68(3):1843-53. PubMed ID: 8107246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.
    Buge SL; Richardson E; Alipanah S; Markham P; Cheng S; Kalyan N; Miller CJ; Lubeck M; Udem S; Eldridge J; Robert-Guroff M
    J Virol; 1997 Nov; 71(11):8531-41. PubMed ID: 9343211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
    Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
    AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against SIV infection in macaques by immunization with inactivated virus from the BK28 molecular clone, but not with BK28-derived recombinant env and gag proteins.
    Mills KH; Page M; Chan WL; Kitchin P; Stott EJ; Taffs F; Jones W; Rose J; Ling C; Silvera P
    J Med Primatol; 1992; 21(2-3):50-8. PubMed ID: 1433267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection.
    Giavedoni LD; Planelles V; Haigwood NL; Ahmad S; Kluge JD; Marthas ML; Gardner MB; Luciw PA; Yilma TD
    J Virol; 1993 Jan; 67(1):577-83. PubMed ID: 8416384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
    Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
    J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.
    Benson J; Chougnet C; Robert-Guroff M; Montefiori D; Markham P; Shearer G; Gallo RC; Cranage M; Paoletti E; Limbach K; Venzon D; Tartaglia J; Franchini G
    J Virol; 1998 May; 72(5):4170-82. PubMed ID: 9557706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.
    Connor RI; Montefiori DC; Binley JM; Moore JP; Bonhoeffer S; Gettie A; Fenamore EA; Sheridan KE; Ho DD; Dailey PJ; Marx PA
    J Virol; 1998 Sep; 72(9):7501-9. PubMed ID: 9696847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses to SIVmne envelope glycoproteins protect macaques from homologous SIV infection.
    Hu SL; Travis BM; Stallard V; Abrams K; Misher L; Moran P; Zarling JM; Langlois AJ; Kuller L; Morton WR
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1489-94. PubMed ID: 1466988
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251.
    Lü X; Kiyono H; Lu D; Kawabata S; Torten J; Srinivasan S; Dailey PJ; McGhee JR; Lehner T; Miller CJ
    AIDS; 1998 Jan; 12(1):1-10. PubMed ID: 9456249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
    Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
    Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.